TEAM

No Caption

Dr. Jia Huidong
International academic leader

• Director of regenerative medicine research center,
• Former Senior Research Fellow,
• Institute of Biomedical Engineering, University of Oxford

An interdisciplinary, regenerative medicine and clinical treatment technology expert with a background in clinical medicine practice. With the goal of transforming scientiﬁc research results into applicable therapeutic technologies, he has been engaged in regenerative medicine research based on stem cells and tissue engineering technology for 20 years.

• Professional member of the International Stem Cell Research Society,
• Member of the British Extracellular Matrix Research Society,
• Member of the British Royal Society of Physiology and Medicine.

Have core technologies for biomedical research and industrialization with independent intellectual property rights, and provide solutions for clinical cell and tissue engineering practices.

Prof. Wen Xuejun

• Professor of Lifetime Chair at Virginia Commonwealth University
• Fellow of the American Institute of Medical and Biological Engineering,
• founder of NOVIS anti-aging technology in USA PROFESSOR

Specialties:
•Brain damage
•Vascular reconstruction.
•nerve regeneration

Professor Meng Songdong

• Researcher and Group Leader at the Institute of Microbiology,
Chinese Academy of Sciences
• Doctoral Supervisor

Graduated in 1998 from the Shenyang Institute of Applied Ecology, Chinese Academy of Sciences, with a Ph.D. in Science. Subsequently, completed postdoctoral research and served as an Instructor at the Institute of Microbiology, Chinese Academy of Sciences, and at the University of Texas Southwestern Medical Center. In 2007, was selected for the Chinese Academy of Sciences’ “Hundred Talents Program,” becoming a Researcher and Group Leader at the Institute of Microbiology. Serves as Associate Editor of the journal *MiCrORNA*.

Currently focuses on research in T-cell immune mechanisms related to hepatitis B virus (HBV) and influenza virus, including HBV-induced liver cancer, breast cancer, virus-host interaction mechanisms, and the development of therapeutic vaccines and targeted drugs. Has published over 40 SCI papers, with articles in *The Lancet*, *Hepatology*, and *PNAS*, and holds 1 PCT patent in the U.S. and 11 national invention patents, with applications for an additional 10 national patents. Has led multiple national projects, including the 973 and 863 Programs and major science and technology projects.